Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
CanSino Biologics, Inc. Class H ( (HK:6185) ) has shared an update.
CanSino Biologics Inc. announced its unaudited interim results for the six months ending June 30, 2025. The announcement, which complies with the Hong Kong Stock Exchange’s listing rules, highlights the company’s financial performance and operational updates. The interim report will be made available to shareholders and published on relevant websites, reflecting the company’s commitment to transparency and stakeholder engagement.
The most recent analyst rating on (HK:6185) stock is a Hold with a HK$52.00 price target. To see the full list of analyst forecasts on CanSino Biologics, Inc. Class H stock, see the HK:6185 Stock Forecast page.
More about CanSino Biologics, Inc. Class H
CanSino Biologics Inc. is a biotechnology company based in China, primarily focused on the development and production of innovative vaccines. The company operates in the biopharmaceutical industry and is known for its contributions to vaccine technology, targeting both domestic and international markets.
Average Trading Volume: 2,125,199
Technical Sentiment Signal: Buy
Current Market Cap: HK$15.23B
For detailed information about 6185 stock, go to TipRanks’ Stock Analysis page.